Effect of the human endotoxin challenge on tedizolid tissue penetration.
antibiotics
antimicrobials
drug distribution
endotoxaemia
inflammation
lipopolysaccharide (LPS)
microdialysis
pharmacokinetics
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
30
09
2022
received:
17
05
2022
accepted:
05
10
2022
pubmed:
13
10
2022
medline:
22
12
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
The effects of the human endotoxin challenge on tissue pharmacokinetics are unknown. In the present study, we aimed to assess the effect of the endotoxin challenge on interstitial fluid pharmacokinetics of tedizolid in healthy volunteers using intramuscular microdialysis. Eight healthy male subjects were treated with 200 mg of tedizolid phosphate for 6 days. On Day 6, an intravenous bolus of lipopolysaccharide (LPS) (2 ng/kg body weight) was administered. LPS infusion did not affect plasma pharmacokinetics of tedizolid. In contrast, following LPS infusion, median muscle tissue fAUC (0.83 [0.75-1.15] vs. 1.14 [1.11-1.43] mg × h/L, P = .0078) and muscle tissue fC
Identifiants
pubmed: 36223278
doi: 10.1111/bcp.15564
pmc: PMC10092186
doi:
Substances chimiques
tedizolid
97HLQ82NGL
Anti-Bacterial Agents
0
Endotoxins
0
Lipopolysaccharides
0
Oxazolidinones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-420Informations de copyright
© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
AAPS J. 2013 Jan;15(1):95-103
pubmed: 23065438
Horm Metab Res. 2011 Oct;43(11):754-9
pubmed: 22009369
Antimicrob Agents Chemother. 2003 Jan;47(1):371-4
pubmed: 12499216
Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:232-8
pubmed: 26813616
J Antimicrob Chemother. 2022 Apr 27;77(5):1424-1431
pubmed: 35165727
Clin Pharmacol Ther. 2014 Oct;96(4):418-22
pubmed: 25236665
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29109162
Br J Clin Pharmacol. 2023 Jan;89(1):416-420
pubmed: 36223278
Shock. 1996 Apr;5(4):251-7
pubmed: 8721384
J Vis Exp. 2016 May 16;(111):
pubmed: 27213711
Biomed Chromatogr. 2020 Jun;34(6):e4820
pubmed: 32115736
Int J Antimicrob Agents. 2012 Jul;40(1):51-4
pubmed: 22584101
Clin Pharmacokinet. 2022 May;61(5):593-617
pubmed: 35218003
Clin Pharmacol Ther. 1999 Dec;66(6):554-62
pubmed: 10613610
Clin Pharmacol Ther. 2008 Jun;83(6):809-11
pubmed: 18488052
Blood. 2005 Mar 15;105(6):2350-5
pubmed: 15522962
Antimicrob Agents Chemother. 1999 Aug;43(8):2056-8
pubmed: 10428936
Crit Care. 2005 Apr;9(2):R157-64
pubmed: 15774049
Eur J Pharm Sci. 2019 Apr 1;131:218-229
pubmed: 30731238
Antimicrob Agents Chemother. 2016 May 23;60(6):3617-25
pubmed: 27044549
J Antimicrob Chemother. 2013 Apr;68(4):895-9
pubmed: 23212112
Biochem Pharmacol. 2009 Sep 15;78(6):539-52
pubmed: 19413999
Eur J Pharm Sci. 2005 May;25(1):1-24
pubmed: 15854796
Shock. 2006 Apr;25(4):358-62
pubmed: 16670637